Description
Description
Tesamorelin is a synthetic polypeptide that acts on growth hormone-producing cells in the pituitary gland and is usually metabolized locally by receptor-bearing cells. As a polypeptide, tesamorelin is unlikely to have direct cytotoxicity. Allergic responses to its administration did not elicit hepatic or systemic hypersensitivity responses.
The recommended dose is 2 mg per day administered by subcutaneous injection. Side effects are not common but may include injection site reactions, itching, arthralgia, myalgia and peripheral edema. Tesamorelin increases IGF-1 levels and monitoring for elevations during treatment is recommended. Potential and rare adverse events include stimulation of malignant tumor growth, glucose intolerance, diabetes, and hypersensitivity reactions.
Reviews
There are no reviews yet.